AUB ScholarWorks

Cyclooxygenase-1, but not -2, is upregulated in NB4 leukemic cells and human primary promyelocytic blasts during differentiation

Show simple item record

dc.contributor.author Rocca B.
dc.contributor.author Morosetti R.
dc.contributor.author Habib A.
dc.contributor.author Maggiano N.
dc.contributor.author Zassadowski F.
dc.contributor.author Ciabattoni G.
dc.contributor.author Chomienne C.
dc.contributor.author Papp B.
dc.contributor.author Ranelletti F.O.
dc.contributor.editor
dc.date Aug-2004
dc.date.accessioned 2017-10-05T15:37:21Z
dc.date.available 2017-10-05T15:37:21Z
dc.date.issued 2004
dc.identifier 10.1038/sj.leu.2403407
dc.identifier.isbn
dc.identifier.issn 08876924
dc.identifier.uri http://hdl.handle.net/10938/15650
dc.description.abstract Cyclooxygenase (COX)-1 or -2 and specific prostaglandin (PG) synthases catalyze the formation of various PGs. We investigated the expression and activity of COX-1 and -2 during granulocyte-oriented maturation induced by all-trans-retinoic acid (ATRA) of NB4 cells, originated from a human acute promyelocytic leukemia (APL), and in blasts from APL patients. The expression of COX isoenzymes or prostaglandin synthases was also investigated in circulating granulocytes and human bone marrow. COX-1 was expressed and enzymatically active in NB4 cells and primary blasts. COX-1 mRNA and protein were induced by ATRA. COX-1 protein increased approximately 2-3.5-fold by culture day 3 in NB4 cells and primary blasts, while basal COX-2 expression was very low and unaffected by ATRA. COX-1-dependent PGE2 biosynthesis increased during differentiation approx. 5-fold. Indomethacin and the selective COX-1 inhibitor SC-560, but not selective COX-2 inhibition, impaired NB4 differentiation, reducing NADPH-oxidase activity, CD11b and CD11c expression. The immunohistochemistry of granulocytes and myeloid precursors in the bone marrow showed a large prevalence of COX-1 as compared to COX-2. In conclusion, COX-1 is induced during ATRA-dependent maturation and appears to contribute to myeloid differentiation both in vitro and ex vivo, and COX-1 activity may potentiate the differentiation of human APL. © 2004 Nature Publishing Group All rights reserved.
dc.format.extent
dc.format.extent Pages: (1373-1379)
dc.language English
dc.publisher LONDON
dc.relation.ispartof Publication Name: Leukemia; Publication Year: 2004; Volume: 18; no. 8; Pages: (1373-1379);
dc.relation.ispartofseries
dc.relation.uri
dc.source Scopus
dc.subject.other
dc.title Cyclooxygenase-1, but not -2, is upregulated in NB4 leukemic cells and human primary promyelocytic blasts during differentiation
dc.type Article
dc.contributor.affiliation Rocca, B., Department of Internal Medicine, Catholic University School of Med., Largo A. Gemelli 8, 00168 Rome, Italy
dc.contributor.affiliation Morosetti, R., Department of Neuroscience, Catholic University School of Med., Rome, Italy
dc.contributor.affiliation Habib, A., Dept. of Biochem.-Internal Medicine, American University of Beirut, Beirut, Lebanon
dc.contributor.affiliation Maggiano, N., Department of Pathology, Catholic University School of Med., Rome, Italy
dc.contributor.affiliation Zassadowski, F., Lab. de Biol. Cell. Hematopoietique, Institut Universitaire d'Hematologie, Hôpital Saint-Louis, Paris, France
dc.contributor.affiliation Ciabattoni, G., Department of Drug Sciences, G D'Annunzio Univ. of Chieti, Chieti, Italy
dc.contributor.affiliation Chomienne, C., Lab. de Biol. Cell. Hematopoietique, Institut Universitaire d'Hematologie, Hôpital Saint-Louis, Paris, France
dc.contributor.affiliation Papp, B., Lab. de Biol. Cell. Hematopoietique, Institut Universitaire d'Hematologie, Hôpital Saint-Louis, Paris, France
dc.contributor.affiliation Ranelletti, F.O., Department of Histology, Catholic University School of Med., Rome, Italy
dc.contributor.authorAddress Rocca, B.; Department of Internal Medicine, Ctr. Ricerche Fisiopatol. Emostasi, Università Cattolica, Largo A. Gemelli 8, 00168 Rome, Italy; email: b.rocca@tiscali.it
dc.contributor.authorCorporate University: American University of Beirut Medical Center; Faculty: Faculty of Medicine; Department: Internal Medicine;
dc.contributor.authorDepartment Internal Medicine
dc.contributor.authorDivision
dc.contributor.authorEmail b.rocca@tiscali.it
dc.contributor.faculty Faculty of Medicine
dc.contributor.authorInitials Rocca, B
dc.contributor.authorInitials Morosetti, R
dc.contributor.authorInitials Habib, A
dc.contributor.authorInitials Maggiano, N
dc.contributor.authorInitials Zassadowski, F
dc.contributor.authorInitials Ciabattoni, G
dc.contributor.authorInitials Chomienne, C
dc.contributor.authorInitials Papp, B
dc.contributor.authorInitials Ranelletti, FO
dc.contributor.authorOrcidID
dc.contributor.authorReprintAddress Rocca, B (reprint author), Catholic Univ, Ctr Ric Fisiopatol Emostasi, Dept Internal Med, Sch Med, Largo A Gemelli 8, I-00168 Rome, Italy.
dc.contributor.authorResearcherID
dc.contributor.authorUniversity American University of Beirut Medical Center
dc.description.cited BAZAN NG, 1994, P NATL ACAD SCI USA, V91, P5252, DOI 10.1073-pnas.91.12.5252; BERK LB, 1990, INT J RADIAT ONCOL, V18, P1387; Chen ZX, 1997, CHINESE MED J-PEKING, V110, P783; DATTA MC, 1985, PROSTAGLANDINS, V29, P561, DOI 10.1016-0090-6980(85)90080-2; Degraeve F, 2001, J BIOL CHEM, V276, P46849, DOI 10.1074-jbc.M104197200; DERTINGER SD, 1995, MUTAT RES-FUND MOL M, V328, P55, DOI 10.1016-0027-5107(94)00195-B; Dogne JM, 2001, CARDIOVASC DRUG REV, V19, P87; Duprez E, 1996, ONCOGENE, V12, P2451; Dupuis F, 1997, J LIPID MEDIAT CELL, V16, P117, DOI 10.1016-S0929-7855(97)00007-2; FONTAGNE J, 1980, EXP HEMATOL, V8, P1157; FUTAKI N, 1994, PROSTAGLANDINS, V47, P55, DOI 10.1016-0090-6980(94)90074-4; GIANNI M, 1995, BLOOD, V85, P3619; Goldschmidt N, 2003, LEUKEMIA LYMPHOMA, V44, P1433, DOI 10.1080-1042819031000076963; Gonchar MV, 1998, BIOCHEM BIOPH RES CO, V249, P829, DOI 10.1006-bbrc.1998.9236; HANSON WR, 1985, RADIAT RES, V103, P196, DOI 10.2307-3576574; HOFF T, 1993, FEBS LETT, V320, P38, DOI 10.1016-0014-5793(93)81653-H; HONDA A, 1986, BIOCHIM BIOPHYS ACTA, V877, P423, DOI 10.1016-0005-2760(86)90208-0; HONDA A, 1992, EUR J PHARMACOL, V229, P217; HONDA A, 1990, BIOCHEM J, V272, P259; Ishiguro S, 1998, PROSTAG OTH LIPID M, V56, P145, DOI 10.1016-S0090-6980(98)00051-3; Jiang LL, 1997, BIOCHEM BIOPH RES CO, V232, P626, DOI 10.1006-bbrc.1997.6345; Jiang YJ, 2003, BBA-MOL CELL BIOL L, V1633, P51, DOI 10.1016-S1388-1981(03)00072-6; Kastner P, 2001, ONCOGENE, V20, P7178, DOI 10.1038-sj.onc.1204757; Khanna-Gupta A, 2000, BLOOD, V95, P3734; Kirtikara K, 1998, J EXP MED, V187, P517, DOI 10.1084-jem.187.4.517; Kwaan HC, 2002, HEMATOL ONCOL, V20, P33, DOI 10.1002-hon.687; Launay S, 1999, BLOOD, V93, P4395; Lee KH, 2002, BIOCHEM BIOPH RES CO, V296, P1125, DOI 10.1016-S0006-291X(02)02043-0; Lorenz M, 1999, EXP HEMATOL, V27, P1494, DOI 10.1016-S0301-472X(99)00087-9; Maloney CG, 1998, J IMMUNOL, V160, P1402; Morosetti R, 1997, BLOOD, V90, P2591; Murate T, 2002, J BIOL CHEM, V277, P9936, DOI 10.1074-jbc.M111594200; NUSING RM, 1995, EUR J BIOCHEM, V227, P130, DOI 10.1111-j.1432-1033.1995.tb20368.x; Ohno R, 2003, LEUKEMIA, V17, P1454, DOI 10.1038-sj.leu.2403031; PELUS LM, 1983, BLOOD, V62, P158; PIANTELLI M, 1983, CLIN IMMUNOL IMMUNOP, V28, P350, DOI 10.1016-0090-1229(83)90102-2; Pouliot M, 1998, FASEB J, V12, P1109; Quenech'Du N, 1998, LEUKEMIA, V12, P1829, DOI 10.1038-sj.leu.2401171; Rocca B, 1999, J CLIN INVEST, V103, P1469, DOI 10.1172-JCI6400; Rocca B, 2002, EUR J IMMUNOL, V32, P1482, DOI 10.1002-1521-4141(200205)32:51482::AID-IMMU14823.0.CO;2-O; Rocca B, 2002, INT IMMUNOPHARMACOL, V2, P603, DOI 10.1016-S1567-5769(01)00204-1; Rocca B, 2002, P NATL ACAD SCI USA, V99, P7634, DOI 10.1073-pnas.112202999; Roussel MJS, 2001, ONCOGENE, V20, P7287, DOI 10.1038-sj.onc.1204863; RUCHAUD S, 1994, P NATL ACAD SCI USA, V91, P8428, DOI 10.1073-pnas.91.18.8428; SANDUJA SK, 1991, BLOOD, V78, P3178; Schneider N, 2001, J NEUROCHEM, V77, P416, DOI 10.1046-j.1471-4159.2001.00264.x; SELLMAYER A, 1994, PROSTAGLANDINS, V47, P203; SHIBATA Y, 1994, BLOOD, V83, P3316; SMITH CJ, 1993, BIOCHEM BIOPH RES CO, V192, P787, DOI 10.1006-bbrc.1993.1483; Smith CJ, 1998, P NATL ACAD SCI USA, V95, P13313, DOI 10.1073-pnas.95.22.13313; Smith WL, 2001, J CLIN INVEST, V107, P1491, DOI 10.1172-JCI13271; Suzuki Y, 1999, BLOOD, V93, P4264; Ueno N, 2001, J BIOL CHEM, V276, P34918, DOI 10.1074-jbc.M100429200; ULICH TR, 1986, AM J PATHOL, V124, P53; Xu XM, 1997, J BIOL CHEM, V272, P6943
dc.description.citedCount 16
dc.description.citedTotWOSCount 16
dc.description.citedWOSCount 15
dc.format.extentCount 7
dc.identifier.articleNo
dc.identifier.coden LEUKE
dc.identifier.pubmedID 15190260
dc.identifier.scopusID 4344614136
dc.identifier.url
dc.publisher.address MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
dc.relation.ispartofConference
dc.relation.ispartofConferenceCode
dc.relation.ispartofConferenceDate
dc.relation.ispartofConferenceHosting
dc.relation.ispartofConferenceLoc
dc.relation.ispartofConferenceSponsor
dc.relation.ispartofConferenceTitle
dc.relation.ispartofFundingAgency
dc.relation.ispartOfISOAbbr Leukemia
dc.relation.ispartOfIssue 8
dc.relation.ispartOfPart
dc.relation.ispartofPubTitle Leukemia
dc.relation.ispartofPubTitleAbbr Leukemia
dc.relation.ispartOfSpecialIssue
dc.relation.ispartOfSuppl
dc.relation.ispartOfVolume 18
dc.source.ID WOS:000222821500009
dc.type.publication Journal
dc.subject.otherAuthKeyword Acute promyelocytic leukemia
dc.subject.otherAuthKeyword Cyclooxygenases
dc.subject.otherAuthKeyword Granulocytes
dc.subject.otherAuthKeyword Prostaglandins
dc.subject.otherAuthKeyword Retinoic acid
dc.subject.otherChemCAS 5 (4 chlorophenyl) 1 (4 methoxyphenyl) 3 trifluoromethyl 1h pyrazole, 188817-13-2
dc.subject.otherChemCAS indometacin, 53-86-1, 74252-25-8, 7681-54-1
dc.subject.otherChemCAS n (2 cyclohexyloxy 4 nitrophenyl)methanesulfonamide, 123653-11-2
dc.subject.otherChemCAS prostaglandin E2, 363-24-6
dc.subject.otherChemCAS prostaglandin synthase, 39391-18-9, 59763-19-8, 9055-65-6
dc.subject.otherChemCAS reduced nicotinamide adenine dinucleotide phosphate oxidase, 9032-22-8
dc.subject.otherChemCAS retinoic acid, 302-79-4
dc.subject.otherChemCAS Cyclooxygenase 1, EC 1.14.99.1
dc.subject.otherChemCAS Cyclooxygenase 2, EC 1.14.99.1
dc.subject.otherChemCAS Dinoprostone, 363-24-6
dc.subject.otherChemCAS Isoenzymes
dc.subject.otherChemCAS Membrane Proteins
dc.subject.otherChemCAS Prostaglandin-Endoperoxide Synthases, EC 1.14.99.1
dc.subject.otherChemCAS PTGS1 protein, human, EC 1.14.99.1
dc.subject.otherChemCAS PTGS2 protein, human, EC 1.14.99.1
dc.subject.otherChemCAS RNA, Messenger
dc.subject.otherChemCAS Tretinoin, 302-79-4
dc.subject.otherIndex 5 (4 chlorophenyl) 1 (4 methoxyphenyl) 3 trifluoromethyl 1h pyrazole
dc.subject.otherIndex CD11b antigen
dc.subject.otherIndex cyclooxygenase 1
dc.subject.otherIndex cyclooxygenase 1 inhibitor
dc.subject.otherIndex cyclooxygenase 2
dc.subject.otherIndex cyclooxygenase 2 inhibitor
dc.subject.otherIndex glycoprotein p 15095
dc.subject.otherIndex indometacin
dc.subject.otherIndex isoenzyme
dc.subject.otherIndex messenger RNA
dc.subject.otherIndex n (2 cyclohexyloxy 4 nitrophenyl)methanesulfonamide
dc.subject.otherIndex prostaglandin E2
dc.subject.otherIndex prostaglandin synthase
dc.subject.otherIndex reduced nicotinamide adenine dinucleotide phosphate oxidase
dc.subject.otherIndex retinoic acid
dc.subject.otherIndex antigen expression
dc.subject.otherIndex antineoplastic activity
dc.subject.otherIndex article
dc.subject.otherIndex bone marrow cell
dc.subject.otherIndex cancer cell culture
dc.subject.otherIndex cancer inhibition
dc.subject.otherIndex cell differentiation
dc.subject.otherIndex cell maturation
dc.subject.otherIndex controlled study
dc.subject.otherIndex drug selectivity
dc.subject.otherIndex enzyme activity
dc.subject.otherIndex enzyme induction
dc.subject.otherIndex enzyme inhibition
dc.subject.otherIndex ex vivo study
dc.subject.otherIndex granulocyte
dc.subject.otherIndex human
dc.subject.otherIndex human cell
dc.subject.otherIndex immunohistochemistry
dc.subject.otherIndex leukemia cell
dc.subject.otherIndex leukemogenesis
dc.subject.otherIndex myeloid progenitor cell
dc.subject.otherIndex prevalence
dc.subject.otherIndex priority journal
dc.subject.otherIndex promyelocyte
dc.subject.otherIndex promyelocytic leukemia
dc.subject.otherIndex prostaglandin synthesis
dc.subject.otherIndex protein expression
dc.subject.otherIndex upregulation
dc.subject.otherIndex Blood Cells
dc.subject.otherIndex Bone Marrow Cells
dc.subject.otherIndex Cell Differentiation
dc.subject.otherIndex Cell Line, Tumor
dc.subject.otherIndex Cyclooxygenase 1
dc.subject.otherIndex Cyclooxygenase 2
dc.subject.otherIndex Dinoprostone
dc.subject.otherIndex Granulocytes
dc.subject.otherIndex Humans
dc.subject.otherIndex Isoenzymes
dc.subject.otherIndex Leukemia
dc.subject.otherIndex Leukemia, Promyelocytic, Acute
dc.subject.otherIndex Membrane Proteins
dc.subject.otherIndex Myelopoiesis
dc.subject.otherIndex Prostaglandin-Endoperoxide Synthases
dc.subject.otherIndex RNA, Messenger
dc.subject.otherIndex Tretinoin
dc.subject.otherIndex Tumor Cells, Cultured
dc.subject.otherIndex Up-Regulation
dc.subject.otherKeywordPlus TRANS-RETINOIC ACID
dc.subject.otherKeywordPlus PROSTAGLANDIN-G-H SYNTHASE
dc.subject.otherKeywordPlus COLONY-FORMING CELLS
dc.subject.otherKeywordPlus HL-60 CELLS
dc.subject.otherKeywordPlus MYELOID DIFFERENTIATION
dc.subject.otherKeywordPlus THROMBOXANE SYNTHESIS
dc.subject.otherKeywordPlus HUMAN NEUTROPHILS
dc.subject.otherKeywordPlus MONOCYTIC CELLS
dc.subject.otherKeywordPlus RAR-ALPHA
dc.subject.otherKeywordPlus EXPRESSION
dc.subject.otherWOS Oncology
dc.subject.otherWOS Hematology


Files in this item

Files Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record

Search AUB ScholarWorks


Browse

My Account